Interpace Biosciences, Inc.
IDXG· OTC
IDXGInterpace Biosciences, Inc.
Filed Apr 1, 2021 · 10-K · 91 days after period end · 0001493152-21-007629
| Metric | Q4 2020 | Q4 2019 | Q4 2018 | Q4 2017dderived from reported figures |
|---|---|---|---|---|
| Revenue | $9.65M | $4.22M | $5.83M | $4.37M |
| Net Income | -$8.14M | -$10.66M | -$4.30M | $20.01M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
ended Dec 31, 2020 · filed Apr 1, 2021 · 91 d after period end
